Suscribirse

ALLERGEN IMMUNOTHERAPY AND AVOIDANCE - 08/09/11

Doi : 10.1016/S0095-4543(05)70093-2 
William A. Fawcett IV, MD *

Resumen

Classic symptoms of allergic rhinitis were recognized by Bostock4 in the early 1800s, but their cause was unknown. Further observation suggested that pollen caused the hay fever symptoms and that the mucous membranes and the skin of hay-fever–sensitive patients react differently from those of normal individuals.38

Immunotherapy for allergic rhinitis began in the early 1900s. Curtis conducted some of the first experiments in this area when he immunized patients with grass pollen vaccines.10 In 1911, Noon prepared pollen extracts based on the weight of the pollen. These extracts were administered subcutaneously at 1- to 2-week intervals. He observed that patients receiving injections of grass pollen extract had diminished ocular allergen challenge reactions; the response to the administration of these allergens was dose dependent; and large doses of allergen extracts could provoke a systemic reaction.25 Freeman and Cook later reported most patients with favorable outcomes following pollen immunotherapy.9, 13 Immunotherapy antigens expanded to include molds, trees, weeds, house dust mites, and stinging insects. Studies have confirmed the relationship between IgE-mediated sensitivity and nasal/airway responsiveness.

In 1931, the Joint Committee of Survey and Standardization set standards for immunotherapy materials and methods.30 Over the next several decades, controlled studies were done to define the role of allergen immunotherapy for the treatment of allergic rhinitis, allergic conjunctivitis, insect anaphylaxis, and asthma.26

The mechanisms of the allergic response have been defined over the past several decades. The passive transfer of serum from an allergic person to a nonallergic person was characterized by the Prausnitz-Küstner reaction.32 Reaginic antibodies were identified by radioimmunoassay. Ishizaka and Ishizaka isolated the reaginic antibody, and the World Health Organization (WHO) named it IgE.17 Later studies showed a seasonal rise in IgE antibodies in pollen sensitive patients, and clarified T-cell and B-cell cooperation in the production of IgE antibodies.31

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to William A. Fawcett IV, MD, 3030 North Street, Suite 450, Beaumont, TX 77702


© 1998  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 1996 
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 25 - N° 4

P. 869-883 - décembre 1998 Regresar al número
Artículo precedente Artículo precedente
  • BRONCHIAL ASTHMA : Update on the Revised Guidelines for Diagnosis and Management
  • J. Andrew Grant
| Artículo siguiente Artículo siguiente
  • FUTURE ROLE OF THE ALLERGIST-IMMUNOLOGIST
  • Dean D. Metcalfe

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.